Evogene Ltd. EVGN
- Market cap
- $6.3M
- P/E
- 0.0×
Follow EVGN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.50 | 26.60 | 19.80 | 12.60 | 7.50 | 16.00 | 6.00 | 4.50 | 1.20 | 0.93 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 85.00 | 58.40 | 42.00 | 26.50 | 60.00 | 102.40 | 19.00 | 14.40 | 10.40 | 2.42 |
High Price
|
|||
| 240 | 205 | 171 | 143 | 131 | 141 | 137 | 142 | 117 | 52 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 7 | 3 | 2 | 1 | 1 | 1 | 2 | 6 | 6 | 4 |
Revenue
|
|||
| 13.78% | 15.85% | 16.89% | 55.64% | 44.81% | 17.53% | 45.73% | 70.00% | 57.32% | (6.25%) |
Gross Margin
|
|||
| (20) | (21) | (21) | (19) | (26) | (30) | (30) | (26) | (15) | (13) |
EBT
|
|||
| (299.02%) | (616.00%) | (1,189.58%) | (2,535.33%) | (2,516.73%) | (3,272.26%) | (1,776.36%) | (460.76%) | (265.52%) | (350.32%) |
EBT Margin
|
|||
| (20) | (21) | (21) | (19) | (26) | (30) | (30) | (26) | (15) | (13) |
Net Income
|
|||
| 2 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 2 |
Depreciation
|
|||
| 2.57 | 1.32 | 0.68 | 0.29 | 0.37 | 0.23 | 0.41 | 1.23 | 0.98 | 0.49 |
Revenue/Sh
|
|||
| (7.70) | (8.10) | (8.10) | (7.00) | (8.30) | (6.90) | (6.50) | (5.20) | (2.89) | (1.08) |
Earnings/Sh
|
|||
| (4.60) | (6.20) | (5.89) | (6.86) | (6.93) | (6.11) | (5.75) | (4.70) | (3.46) | (1.71) |
Cash Flow/Sh
|
|||
| (0.32) | (0.23) | (0.15) | (0.35) | (0.24) | (0.21) | (0.28) | (0.17) | (0.11) | (0.01) |
Capex/Sh
|
|||
| (4.91) | (6.43) | (6.03) | (7.21) | (7.17) | (6.32) | (6.03) | (4.87) | (3.57) | (1.72) |
Free CF/Sh
|
|||
| 34.31 | 27.02 | 19.53 | 23.38 | 20.20 | 15.69 | 8.44 | 6.25 | 2.60 | 1.52 |
Book Value/Sh
|
|||
| 3 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 6 | 8 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 19.76 | 26.35 | 29.19 | 51.99 | 127.26 | 71.30 | 17.96 | 7.08 | 1.91 | 2.25 |
PS Ratio
|
|||
| 1.48 | 1.28 | 1.01 | 0.65 | 2.33 | 1.05 | 0.86 | 1.39 | 0.72 | 0.72 |
PB Ratio
|
|||
| 6.28 | 5.13 | (1.99) | (10.27) | 80.88 | 13.38 | (3.15) | 1.57 | (0.84) | (1.12) |
EV/Sales
|
|||
| (3.29) | (1.05) | 0.42 | 0.42 | (4.17) | (0.49) | 0.21 | (0.40) | 0.23 | 0.32 |
EV/FCF
|
|||
| (12) | (16) | (15) | (18) | (20) | (25) | (24) | (22) | (20) | (14) |
Op' Cash Flow
|
|||
| (1) | (1) | 0 | (1) | (1) | (1) | (1) | (1) | (1) | 0 |
Capex
|
|||
| (12) | (17) | (16) | (19) | (20) | (26) | (25) | (22) | (20) | (14) |
FCF
|
|||
| 84 | 68 | 50 | 43 | 42 | 50 | 32 | 28 | 3 | 12 |
Working Cap'
|
|||
| — | — | — | 1 | 1 | 1 | 1 | — | — | — |
Total Debt
|
|||
| (88) | (72) | (54) | (47) | (48) | (54) | (35) | (31) | (15) | (13) |
Net Debt
|
|||
| 87 | 69 | 50 | 60 | 57 | 63 | 35 | 29 | 15 | 12 |
Sh' Equity
|
|||
| (18.79%) | (24.01%) | (30.46%) | (27.85%) | (32.63%) | (37.50%) | (40.23%) | (44.54%) | (36.24%) | (28.33%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | (99.16%) | (179.23%) | (202.49%) | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (20.51%) | (26.60%) | (34.69%) | (32.78%) | (39.92%) | (46.21%) | (54.25%) | (75.24%) | (75.75%) | (63.29%) |
ROE
|
|||
Evogene Ltd. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CELZ Creative Medical Technology Holdings, Inc. | $6.4M | 0.0× | Compare |
| BGMS Bio Green Med Solution, Inc. | $6.2M | 0.0× | Compare |
| NIKI Niki BioSolutions, Inc. | $6.2M | 0.0× | Compare |
| KAPA Kairos Pharma, Ltd. | $6.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CANF Can-Fite Biopharma Ltd | $6.5M | 0.0× | Compare |
| PULM Pulmatrix, Inc. | $6.1M | 0.0× | Compare |
| SYBX Synlogic, Inc. | $6.7M | 0.0× | Compare |
| ERNA Ernexa Therapeutics Inc. | $5.9M | 0.0× | Compare |
Evogene Ltd. (EVGN) key facts
- Evogene Ltd. (EVGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, EVGN traded at $0.42, a market capitalization of $6.3 million.
- Return on equity was −63.3% and debt-to-equity 0.00.
Evogene Ltd. (EVGN) Latest News
31 Aug
Evogene responds to dissident shareholders by citing its transformation and commercial progress as a clear path forward. Defense against shareholder criticism highlights strategic progress that may stabilize short-term investor sentiment.
25 Aug
Evogene Ltd. (EVGN) released its Q2 2026 earnings call transcript covering financial results, operational updates and forward outlook. Quarterly earnings details typically produce moderate short-term shifts in valuation and sentiment without guaranteeing major strategic change.
19 Aug
Evogene Ltd. (EVGN) held its Q2 2026 earnings call covering quarterly financial results, operational updates and forward outlook. Q2 2026 earnings figures and guidance directly shape investor views and near-term share price movement.
18 Aug
Evogene Ltd highlighted a strategic pivot to AI-driven drug development in its Q2 2026 earnings call. Strategic pivot to AI-driven drug development signals major directional shift with significant long-term implications.
23 Jul
Evogene partners with ELEO to develop new oral PCSK9 inhibitors. Partnership launches major product development program with potential to shift Evogene competitive positioning and long-term growth.
22 Jul
Evogene Ltd. partners with ELEO Inc. to develop next-generation oral small-molecule PCSK9 pathway inhibitors for hyperlipidemia and cardiovascular diseases. Partnership advances Evogene's PCSK9 inhibitor program in core computational drug-discovery operations.
21 Jul
Cibus Inc's precision-breeding platform and biofragrance scale-up support commercial inflection. Cibus commercial inflection via platform and scale-up advances directly strengthens Evogene positioning and growth prospects.
15 Jul
AgPlenus launches novel AI model for predicting antifungal potency, expanding ChemPass AI for Ag™ capabilities. New AI model expands core platform capabilities in crop protection, likely strengthening Evogene competitive position and pipeline.
9 Jul
Evogene Ltd. partners with Tel Aviv University to launch a drug discovery initiative. Drug discovery initiative with Tel Aviv University marks major strategic move in Evogene core biotech operations.
8 Jul
Evogene partners with Tel Aviv University's Blavatnik Center for Drug Discovery to accelerate AI-driven small-molecule drug discovery. Partnership bolsters Evogene's AI drug discovery capabilities via academic collaboration.
24 Jun
Evogene reaches major milestone in Google Cloud collaboration, advancing ChemPass AI toward autonomous small molecule discovery and optimization. Milestone advances core AI platform via major cloud partner, positioning Evogene for accelerated discovery capabilities.
2 Jun
Evogene subsidiary Biomica successfully completed Phase 1 clinical study of BMC128 live bacterial product combined with Nivolumab. Phase 1 success advances Biomica product pipeline and supports longer-term therapeutic positioning.
28 May
Evogene Ltd reported Q1 2026 earnings with emphasis on new strategic collaborations offset by ongoing financial pressures. Strategic collaborations may moderately support Evogene's innovation pipeline and market positioning without altering core financial trajectory.
20 May
Evogene Ltd. (EVGN) held its Q1 2026 earnings call, outlining financial results, operational updates, and forward-looking strategy in ag-biotech and related fields. Quarterly earnings calls supply fresh financial and strategic data that can moderately shift near-term sentiment and valuation without guaranteeing structural change.
2 Apr
Evogene Ltd. (EVGN) received a Nasdaq notification for failing to meet the $1.00 minimum bid price requirement over 30 consecutive business days, providing 180 calendar days to regain compliance by achieving a $1.00 closing bid price for 10 consecutive business days. Nasdaq minimum bid price deficiency signals delisting risk, moderately impacting investor sentiment and stock liquidity.
31 Mar
Casterra announced successful commercial field trials in Brazil, positioning castor oil as a promising economically viable biofuel feedstock. Successful Brazilian field trials advance Casterra's castor technology toward biofuel commercialization, boosting Evogene's pipeline and investor interest.
13 Mar
Evogene Ltd. (EVGN) Q4 2025 earnings call highlights strategic shifts amid declining revenue. Revenue decline impacts financial performance while strategic shifts offer moderate repositioning potential.
6 Mar
Evogene Ltd. (EVGN) released Q4 2025 earnings call summary detailing quarterly financial results, operational updates, and future outlook. Q4 2025 earnings summary impacts financial performance and investor sentiment but lacks transformative elements.
5 Mar
Evogene Ltd. (EVGN) released its Q4 earnings snapshot reporting financial results for the quarter. Q4 earnings snapshots reveal financial performance that moderately influences market sentiment and short-term stock trajectory.
Evogene Ltd. (EVGN) reported fourth quarter and full year 2025 financial results. Quarterly and annual financial results disclosure affects key financial performance metrics and investor sentiment.
25 Feb
Evogene Ltd. (EVGN) released a letter from its CEO to shareholders. CEO letter to shareholders typically updates on strategy and progress, offering moderate influence on investor sentiment and financial outlook.
17 Feb
Evogene Ltd. (EVGN) and Queensland University of Technology (QUT) announced a collaboration to advance AI-driven cancer therapeutics. Partnership with QUT on AI-driven cancer therapeutics supports Evogene's expansion into oncology innovation.
11 Feb
Evogene Ltd. has partnered with Systasy and LMU University Hospital Munich to develop innovative therapies targeting neutrophil-derived inflammatory diseases. This collaboration aims to leverage Evogene's computational biology platform and Systasy's expertise in drug development to create new treatment options for patients suffering from these conditions. The collaboration could significantly enhance Evogene's product pipeline and market positioning in the therapeutic landscape.
10 Feb
Evogene Ltd. has announced an expanded collaboration with Google Cloud to integrate AI agents into its ChemPass AI™ platform. This partnership aims to enhance the capabilities of ChemPass AI™, which focuses on accelerating the development of novel products in agriculture and biotechnology. The integration of AI agents is expected to improve data analysis and decision-making processes, ultimately driving innovation in the company's offerings. The collaboration with Google Cloud is likely to significantly enhance Evogene's product capabilities and competitive positioning in the biotechnology sector.
Evogene Ltd. announced a warrant inducement transaction aimed at raising approximately $3.4 million in gross proceeds. The transaction involves the issuance of warrants to purchase shares of the company's common stock, which are intended to attract new investors and strengthen the company's financial position. This move is part of Evogene's strategy to enhance its capital resources for ongoing and future projects. The warrant inducement transaction is expected to provide additional capital, which may support future operations and projects.
9 Feb
Evogene Ltd. has appointed Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board. Both professors bring extensive expertise in their respective fields, which is expected to enhance Evogene's capabilities in developing innovative solutions for agriculture and biotechnology. Their appointments are part of Evogene's strategy to strengthen its scientific foundation and drive future growth. The addition of experienced professionals to the advisory board may positively influence product innovation and competitive positioning.
4 Feb
Evogene Ltd. has entered into an exclusive licensing agreement with Shanghai Lishan Biopharmaceuticals Co. for BMC128, a microbiome-based therapeutic targeting renal and lung cancer. This collaboration aims to leverage Evogene's expertise in microbiome research to develop innovative cancer treatments, potentially enhancing patient outcomes in these areas. The licensing agreement represents a significant strategic move that could enhance Evogene's product offerings and market position in the oncology sector.
Evogene Ltd. has entered into an exclusive licensing agreement with Shanghai Lishan Biopharmaceuticals Co. for BMC128, a microbiome-based therapeutic targeting renal and lung cancer. This collaboration aims to leverage Evogene's expertise in microbiome research to develop innovative cancer treatments, enhancing both companies' capabilities in the biopharmaceutical sector. The licensing agreement represents a significant strategic move that could enhance Evogene's product offerings and market position in the oncology space.
7 Jan
Evogene Ltd. has partnered with Unravel Biosciences to develop a groundbreaking therapy aimed at reversing neurological damage caused by demyelinating disorders. This collaboration seeks to leverage both companies' expertise in biotechnology and drug development to create innovative treatment options for patients suffering from these conditions. The collaboration represents a significant strategic move that could enhance Evogene's product offerings and market position in the biotechnology sector.
30 Dec
Evogene Ltd. has appointed Dr. Olga Nissan as its new Vice President of Business Development. Dr. Nissan brings extensive experience in the biotechnology and agricultural sectors, having held various leadership roles in business development and strategic partnerships. Her expertise is expected to enhance Evogene's growth strategy and strengthen its market position. The appointment of a seasoned executive may positively influence business development and strategic partnerships, impacting the company's trajectory.